MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

November 10, 2016

Today is World Pneumonia Day. It's a somewhat abstract concept, associating a specific disease with a specific day, but the reality of pneumonia is very scary and dangerous, and possibly even deadly, for millions and millions of people around the globe.

Each year, pneumonia takes the lives of nearly one million children worldwide, often for want of a vaccine. There is in fact a vaccine to prevent it, something that's commonly administered to children in many western countries, but it’s too expensive for many countries to afford.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

November 10, 2016

Today is World Pneumonia Day. It's a somewhat abstract concept, associating a specific disease with a specific day, but the reality of pneumonia is very scary and dangerous, and possibly even deadly, for millions and millions of people around the globe.

Each year, pneumonia takes the lives of nearly one million children worldwide, often for want of a vaccine. There is in fact a vaccine to prevent it, something that's commonly administered to children in many western countries, but it’s too expensive for many countries to afford.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.